Teen Vulnerability to Irritability: Brain and Estrogen Changes (NCT07544966)
Neurobiological Mechanisms of Susceptibility to Estradiol Fluctuation in Female Adolescents at Risk of Suicide: An Experimental Approach
🩺 Plain-English Summary (8th-Grade Level)
Purpose: Risk of severe psychopathology increases dramatically during adolescence, especially for females. Changes in ovarian steroids across the menstrual cycle produce windows of vulnerability to mood disturbances, particularly during the abrupt withdrawal of estradiol (E2) and progesterone (P4) prior to menses onset. Irrefutable evidence links stress with affective symptoms, potentially mediated by E2-related modifications of frontolimbic connectivity and prefrontal gamma-aminobutyric acid (GABA) inhibitory signaling. The primary objective of this project is to empirically test the impact of E2 and P4 change on vulnerable brain networks associated with irritability and other depressive symptoms in female adolescents at risk of suicide. Participants: The investigators will enroll 50 female adolescents ages 12-16 who are at risk of suicide (i.e., moderate depressive symptoms), and are eligible to receive oral contraceptives and undergo MRI imaging. Procedure: Using a randomized, placebo-controlled, cross-over design, participants will be studied under two conditions: 8 weeks of E2 and P4 stabilization (continuous combined oral contraceptive (COC) to prevent perimenstrual withdrawal) and 8 weeks of placebo, with a 1-month washout after each condition. Each condition will include: 1) daily samples of E2 and P4 urinary metabolites, 2) daily symptom ratings(e.g., irritability, negative affect and suicidal thoughts and behaviors (STBs)), and 3) a neuroimaging session with MRI and magnetic resonance spectroscopy (MRS).
Who can join: Review the eligibility criteria below.
Location: Biomedical Research Imaging Center (BRIC) at UNC — Chapel Hill, North Carolina
Age range: 12 Years to 16 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Biomedical Research Imaging Center (BRIC) at UNC — Chapel Hill, North Carolina
- Carolina Crossing — Chapel Hill, North Carolina
📞 Contact the Study Coordinator
Phone: (919) 843-8084
Email: Elizabeth_Andersen@med.unc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Depression - Major Depressive Disorder
- Racial Disparities in Antidepressant Treatment After a Psychiatric Consultation — Toronto, Ontario
- Sham-Controlled Rapid-Acting Neuromodulation for Depression — Sacramento, California
- Deaf CBT-TS to Reduce Suicide Risk — Rochester, New York
- Group PACBT for Depression — Los Angeles, California
- Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder — Durham, North Carolina
Explore by condition: All Depression - Major Depressive Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.